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Abstract A set of synthetic peptldes derived from the capsid containing p-cresol and purified by reversed-phase HPLC. The amino 
proteins of hepatitis A virus was used to search for B-epitopes. acid analysis of peptides was consistent with their expected composi- 
Peptides from the 115-139 region of the VP1 protein, from the tions. The molecular masses of peptides were confirmed by FAB mass 
69-99 region of the VP2 protein and peptide 137-150 from the spectra. 
VP3 protein were found to react with monoclonal and polyclonal 2.2. Mice 
anti-HAV antibodies. MAPs based on 64--80 and 66--80 frag- BALB/c, CBA, C57B16 and F~(CBA × C~TBI6) strains were obtained 
merits of VP3 were reactive as well. Peptides, their conjugates from the breeding colony at the Central nursery of laboratory animals 
with protein carriers and MAPs were used for antipeptide anti- (Russian Academy of Medical Sciences, Krasnogorsk, Russia). Mice 
body production. Only free peptide 69--99 from the VP2 protein were used at 6 to 8 weeks of age and were of either sex. 
caused formation of HAV binding antibodies. 
2.3. Virus 
Key words." Synthetic peptide; Antigenic determinant; The cell culture-adapted HAS-15 strain was obtained from the Insti- 
HAV binding antibody; Antipeptide antibody; tute of Poliomyelitis and Viral Encephalitides (Moscow Region). 
Monoclonal antibody 2.4. Anti-HAV antibodies 
The IgG fraction from human reconvalescence sera was obtained 
from Institute of Poliomyelitis and Viral Encephalitides (Moscow Re- 
gion). Monoclonal antibodies to HAV were prepared as previously 
1. Introduction described: mAb HB-1 (IgG2a) [6], mAbs B.2.6.8 and 1.2.2.2 [7]. mAbs 
HB-1 and B.2.6.8 were virus neutralizing. 
So far there are no strong data about localization of HAV 2.5. Biotinylation of anti-HAV antibodies 
antigenic sites (B-epitopes). It is anticipated that one immuno- Purified monoclonal and human anti-HAV IgG antibodies were dis- 
dominant neutralization site involves residues of VP3 and VP1 solved in 2 ml of phosphate-buffered saline, pH 8.6 (2 mg/ml) and 100 
HAV capsid proteins [1,2]. Another neutralization domain was ~1 of N-hydroxysuccinimide-biotin in dimethylformamide (1 mg/ml) 
reported to exist in the N-terminal part of VP1 [3,4]. were added. The reaction was allowed to proceed overnight at 8°C or 
2 h at 20°C. The reaction mixture was separated from the free N- 
Recently we reported about searching for HAV B-epitopes hydroxysuccinimide-biotin by ultrafiltration through a YM-30 mem- 
by means of synthetic peptides [5]. We did not detect he signif- brane (Amicon). Biotinylated antibodies were stored at -20°C in glyc- 
icant binding of anti-HAV antibodies to any peptide. Our find- erol. 
ing supported the earlier claim about the conformational na- 
2.6. Peptide-specifie ELISA 
ture of HAV B-epitopes [1]. Binding of anti-HAV antibodies to peptides was determined by solid- 
This study follows on from previous work and is directed at phase ELISAs utilizing microtiter plates (Costar) coated overnight with 
the investigation of the HAV antigenic structure and the search peptide (20/,tg/ml) in PBS or in pH 8.9 carbonate buffer. Wells were 
for immunodominant sites on HAV capsid proteins. In the blocked with 1% BSA for 1 h, and biotinylated anti-HAV antibodies 
were added for 1 h. After washing with PBS containing 0.05% Tween 
present study, the set of synthetic peptides was significantly 20, streptavidin-biotinylated peroxidase (Amersham) was added. After 
enlarged, and monoclonal anti-HAV antibodies along with pol- 15 min of incubation plates were washed and then developed by addi- 
yclonal antibodies were used. tion of o-phenylenediamine in 0.1 M citrate buffer, pH 4.8 (0.5 mg/ml) 
and 0.002% of 1-1202. After 0.5 h the reaction was stopped by the 
2. Materials and methods addition of I M HzSO 4 and the optical density was measured at 492 nm 
using a Multiscan Reader (Labsystems, Finland). Results were consid- 
2.1. Synthetic peptides ered as positive when the signal-noise ratios (S/N) were greater than 
Peptides were synthesized by a solid-phase method on a modernised 2.2. 
Beckman 990 peptide synthesizer using PAM resin and HOBt esters of 
Boc amino acids as described earlier [5]. The synthesized peptides were 2. 7. Antipeptide antisera 
Antisera were produced in mice to each of the selected peptides (free 
or conjugated with KLH or Ova at a ratio of 2 mg KLH to 1 mg peptide 
and 2 mg Ova to 2 mg peptide using a glutaraldehyde coupling reac- 
*Corresponding author. Fax: (7) (095) 335 7103; (7) (095) 335 5844. tion). Mice (three per group) were immunized intraperitoneally with 
antigen (100 jzg of free peptide or 50 ,ug of conjugate) in Freund's 
Abbreviations." HAV, hepatitis A virus; MAP, multiple antigen peptide; complete adjuvant. Three booster injections with the same amount of 
mAb, monoclonal antibody; KLH, keyhole limpet haemocyanin; Ova, antigen in Freund's incomplete adjuvant were given at 15, 30 and 45 
ovalbumin; BSA, bovine serum albumin; ELISA, enzyme-linked im- days after the initial injection. Serum was collected 4 days after the final 
munosorbent assay; PBS, phosphate-buffered saline, booster immunization. 
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!.8. Antipeptide antibody assays was also not reactive. MAP based on VP3-(66-80) interacted 
Binding of antipeptide antisera to HAV were determined by solid- with mAb 1.2.2.2 and slightly less with the IgG fraction. 
)base EL1SAs. Microtiter plates were coated overnight with human Lengthening of the monomer in MAP-(64-80) by two residues 
mti-HAV serum at a 1:20000 dilution. Wells were blocked with 1% 
3SA prior to the addition of the HAV preparation. After overnight dramatically increased the reactivity of the last with all anti- 
ncubation and washing, serial 2-fold dilutions of mouse antisera were bodies. 
tdded. Anti-species antibodies were commercial horseradish peroxi- Peptides VP3-(45-57), VP3-(137 150) and VP2-(69-99) 
tase conjugates (Sigma). bound only to mAb 1.2.2.2. Peptides corresponding to the 
!.9. Peptide blocking ELISA N-terminal part of the 107-139 region of VP1 (107-126, 112- 
Microtiter plates were coated with HAV or synthetic peptides and 126 and 115-126) did not react with any anti-HAV antibodies, 
he anti-VP2-(69-99) serum (1:200) preliminary incubated with the whereas those corresponding to the C-terminal part of this 
:ompeting peptide (10 ,ug/ml in 0.1 M PBS) was added, region (117-139 and 126-139) bound to the all three mAbs. 
Peptide VPI-(115-139) which is two residues horter than VP1- 
3. Results and discussion (117 139) interacted only with mAb 1.2.2.2. It is not inconceiv- 
able that peptide longation causes the change of its conforma- 
Peptides were derived as probable B-epitopes based on com- tion and in consequence its antigenic properties. The same 
rater analysis methods of HAV proteins equences a  described conclusions can be drawn regarding peptides 69-99 and 80-99 
;lsewhere [8]. In addition we synthesized multiple antigen pep- of VP2. 
:ides based on 64-80 and 66-80 segments of VP3. It was re- It can be seen from Table 2 that peptides VP1-(126-139) and 
~orted that anti-peptide antibodies raised after immunisation VP2-(80 99) having non-related structures bound to all anti- 
with the peptide VP3-(62-75) conjugated with KLH were able bodies. Furthermore, one can notice that the same antibodies 
o bind native HAV [9]. All synthetic peptides and MAPs reacted with the peptides of variable composition and were 
Table 1) were tested for binding to anti-HAV antibodies in derived from different proteins. At present we have no plausible 
~olid-phase ELISA. We did not detect binding of any peptides explanation for these facts, but a related phenomenon was 
-17, 2-33, 6-17, 11-25 and 10-33 from VP1 overlapping the described earlier [10 12]. 
• eported B-epitope 11-25 from VP1 [3] neither to polyclonal MAPs, VPI-(115-139), VPI-(117-139), VP2-(69-99), VP2- 
lor to monoclonal nti-HAV antibodies. Peptide VP3-(62-75) (80 99) binding to anti-HAV antibodies, VPl-(10-33) and 
['able 1 
;ynthetic peptides from the HAV capsid proteins 
'rotein Segment Amino acid sequence 
/P1 1 17 VGDDSGGFSTTVSTEQN 
2 33 GDDSGGFSTTVSTEQNVPDPQVGITTXRDLKG 
6-17 GGFSTTVSTEQN 
10-33 TTVS TEQNVPDPQVGI TTXRDLKG 
11~5 TVSTEQNVPDPQVGI 
64-75 KVPETFPELKPG 
75 85 GESRHTSDHXS 
75-92 GESRHTSDHMS I YKFXGR 
107-126 YTFPITLSSTSNPPHGLPST 
112-126 TLSSTSNPPHGLPST 
115 126 STSNPPHGLPST 
115 139 STSNPPHGLPSTLRWFFNLFQLYRG 
117 139 SNPPHGLPSTLRWFFNLFQLYRG 
126-I 39 TLRWFFNLFQLYRG 
180 195 DYKTALGAVRFNTRRT 
20%221 YAVSGALDGLGDK 
276-298 XSRIAAGDLES SVDDPRSEEDRR 
288 298 VDDPRSEEDRR 
290-299 DPRSEEDRRF 
[P2 42-62 PLKTSVDKPGSKKTQGEKFFL 
65-85  SADWLTTHALFHEVAKLDVVK 
69-99 LTTHAL FHEVAKLDVVKLLYNEQFAVQGLLR 
73 85 ALFHEVAKLDVVK 
80-99 KLDWKLLYNEQFAVQGLLR 
178 190 PVWELTIRVWSEL 
7P3 45-57 GIKITHFTTWTS I 
62 75 AQFPFNASDSVGQQ 
137-150 PGNEL I DVTG I TLK 
235-246 APLYHAXDVTTQ 
IP4 l 23 MNMSKQGI FQTVGSGLDHI LSLA 
¢IAP-(64-80) (FPFNASDSVGQQIKVI P) 8-K4-K2-K-G 
¢IAP-(66-80) (FNASDSVGQQIKVI P) 8-K4-K2-K-G 
( : Nle 
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VP3-(62-75) overlapping already described B-epitopes were Table 3 
chosen for the production of antipeptide antisera. Antipeptide Immunogenicity of synthetic antigens* 
antibodies were obtained after immunization with the free pep- Antigen Mouse H-2 Antipeptide Binding of 
tides VP- 1-(115-139), VP- 1-(117-139), VP-2-(69-99) and VP-4- strain sera antipeptide 
sera to 
(1-23) and their conjugates with ovalbumine. Mouse strains for native 
immunization with free peptides were chosen based on antigen- HAV 
depending proliferation of lymph node T-cells [13]. Peptide 
conjugates were injected into BALB/c mice. VPl-(10~33)-KLH BALB/c d 3 < 1 
The presence of antipeptide antibodies in animal sera was vP1-(115-139) C57B16 b 3.5 < 1 
VPI-(115-139)-Ova BALB/c d 3.2 < 1 
tested by ELISA. Pooled sera from three mice immunized with VPI-(117-139) C57B16 b 2.5 < l 
appropriate antigen were used. Of the free peptides only VP-1- VPl-(l17-139)-Ova BALB/c d 3.2 < 1 
(115-139), VP-1-(117-139), VP-2-(69-99) and VP-4-(1-23) in- VP2-(69-99) BALB/c d 4.2 3.2 
duced antipeptide antibodies (Table 3). VP2-(80-99)-KLH BALB/c d 3 < 1 
VP3-(62-75)-KLH BALB/c d 3 < 1 
Peptide VP2-(69-99) contains two lysine residues at positions VP4-(1-23) C57B16 b 4 < 1 
80 and 85 which can react with glutaraldehyde uring the con- MAP-(64~80) BALB/c d 4.8 < 1 
jugation reaction. We did not obtain antipeptide antibodies MAP-(66-80) BALB/c d 5.1 < 1 
after immunization with the conjugate VP2-(69-99)-Ova. It can *Titre of antibodies on the lg scale. 
be assumed that Lys 8° and Lys 85 participate in forming of the 
antigenic determinant localized on the N-terminal part of VP2- 
(69-99). Peptides VP-1-(115-139) and VP-I-(117-139) conju- 
gated to ovalbumine also raised antipeptide antibodies. (69-99) did not block the binding IgG of pooled reconvalescent 
Free peptides VPl-(10-33) and VP3-(62 75) did not induce sera to virus (data not shown). It follows that the B-epitope 
antipeptide antibodies, while immunization with the peptides mimicked by VP2-(69-99) is not immunodominant or in the 
conjugated to KLH resulted in peptide binding antibodies pro- process of disease development antibodies are formed directed 
duction. These data, combined with the results of T-cell epi- to epitope(s) differing from those represented by VP2-(69-99). 
topes determination [13], indicate the low immunogenicity of It is a distinct possibility that this peptide represents the B- 
VPI-(10-33) and VP3-(62-75). High titre antisera were ob- epitope recognized by IgM antibodies that are in patient sera 
tained after immunization with both MAPs. However, antisera on the initial step of the disease. The result obtained is in 
to MAP-(64-80) and MAP-(66-80) reacted weakly with the agreement with published ata [14]. 
peptide VP3-(62-75) (data not shown). Obviously a new anti- VP2-(69-99) and VP2-(80-99) blocked the binding anti-VP2- 
genic determinant is formed in MAP constructs to which the (69-99) serum both to the source peptide and HAV (data not 
main antibody response is directed. This B-epitope is localized shown). Thus, the interaction between antigens and peptide- 
close to the C-terminal part of peptides and is shared by both specific antibodies i highly specific. Antiserum to VP2-(69-99) 
MAPs, since antisera obtained after immunization with the one reacted with VP2-(80-99) (titres 1/10000), but showed no bind- 
MAP bound to the homologues antigen and to other MAP with ing to VP2-(73-85) and VP2-(65-85). These latter also had no 
about the same titres (data not shown), effect on binding of the antiserum both to VP2-(69-99) and 
Antipeptide antisera were also tested in ELISA for their HAV. Thus, from the results obtained it may be deduced that 
ability to react with native HAV. Sera from non-immunized the B-epitope is located near to C-terminal part of 69-99 frag- 
mice and mice immunized with KLH and Ova served as con- ment of HAV VP2. 
trois. Only antiserum to free VP2-(69-99) was found to react 
with native HAV (Table 3). At the same time antisera to VP2- Acknowledgements: This work was supported in part by Grant 94-04- 
11180-a from the Russian Fund for Basic Research. 
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